Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607127 | 0.86 | ALDH1A1 (0.42) | ALDH1A1EPHX1ESR1ACP3NR3C2 | |
| SCHEMBL6722066 | 0.83 | ESR1 (0.41) | ALDH1A1ESR1ACP3ROCK2TSHR | |
| SCHEMBL1928791 | 0.83 | ACP3 (0.43) | ALDH1A1ESR1ACP3TSHRLMNA | |
| SCHEMBL29053314 | 0.81 | ESR1 (0.39) | ALDH1A1ESR1ACP3ROCK2TSHR | |
| SCHEMBL10515048 | 0.81 | TSHR (0.55) | ALDH1A1EPHX1TSHRLMNAHSD17B10 | |
| Water SCHEMBL8545817 | 0.81 | ACP3 (0.42) | ALDH1A1ESR1ACP3TSHRLMNA | |
| SCHEMBL5504222 | 0.81 | EPHX1 (0.41) | ALDH1A1EPHX1TSHRLMNAHSD17B10 | |
| SCHEMBL14678497 | 0.81 | EPHX1 (0.62) | ALDH1A1EPHX1NR3C2HSD17B10TDP1 | |
| SCHEMBL11082535 | 0.81 | ALDH1A1 (0.41) | ALDH1A1EPHX1ESR1ACP3NR3C2 | |
| SCHEMBL15502391 | 0.80 | EPHX1 (0.40) | ALDH1A1EPHX1TSHRLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | claimed |
| US-20240368209-A1 | GEMCITABINE ANTICANCER DERIVATIVE AND ANTICANCER PHARMACEUTICAL USE | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4407019-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2024-07-31 | — | — | EP | disclosed |
| EP-4365182-A1 | GEMCITABINE ANTICANCER DERIVATIVE AND ANTICANCER PHARMACEUTICAL USE | Ascentawits Pharmaceuticals, Ltd. (CN) | 2024-05-08 | — | — | EP | disclosed |
| EP-3365334-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
| CN-103694277-A | Red-phosphorescence organic light emitting diode (LED) | GUANMAT OPTOELECTRONIC MATERIALS JIANGXI INC | 2014-04-02 | — | — | CN | disclosed |
| US-7964593-B2 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2011-06-21 | — | — | US | disclosed |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| US-7645887-B2 | 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide | UCB PHARMA, S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368209-A1 | GEMCITABINE ANTICANCER DERIVATIVE AND ANTICANCER PHARMACEUTICAL USE | AKR1C3, AKR1C2, AKR1A1 | ALDH1A1 70/4885EPHX1 2089/4885ESR1 2836/4885 |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | AANAT, TPH2, CYP1A2 | ALDH1A1 308/4885EPHX1 1156/4885ESR1 3156/4885 |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | AANAT, TPH2, CYP1A2 | ALDH1A1 308/4885EPHX1 1156/4885ESR1 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.